login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
TIZIANA LIFE SCIENCES LTD (TLSA) Stock News
USA
- NASDAQ:TLSA -
BMG889121031
-
Common Stock
1.76
USD
-0.06 (-3.3%)
Last: 9/23/2025, 8:16:27 PM
1.75
USD
-0.01 (-0.57%)
Pre-Market:
9/24/2025, 8:00:00 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
TLSA Latest News, Press Relases and Analysis
All
Press Releases
43 minutes ago - By: Tiziana Life Sciences Ltd.
Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress
43 minutes ago - By: Tiziana Life Sciences Ltd.
Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress
9 days ago - By: Tiziana Life Sciences Ltd.
Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury
15 days ago - By: Tiziana Life Sciences Ltd.
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
15 days ago - By: Tiziana Life Sciences Ltd.
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
19 days ago - By: Tiziana Life Sciences Ltd.
Tiziana Life Sciences Announces Purchase of Shares by Chairman
19 days ago - By: Tiziana Life Sciences Ltd.
Tiziana Life Sciences Announces Purchase of Shares by Chairman
a month ago - By: Tiziana Life Sciences Ltd.
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy
a month ago - By: Tiziana Life Sciences Ltd.
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy
a month ago - By: Tiziana Life Sciences Ltd.
FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy
a month ago - By: Tiziana Life Sciences Ltd.
FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy
2 months ago - By: Benzinga
- Mentions:
UBER
LCID
TSLA
Lucid Is Now Shipping Adapters That Let Customers Access Elon Musk-Led Tesla's Supercharger Network
2 months ago - By: Tiziana Life Sciences Ltd.
Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient
3 months ago - By: Benzinga
- Mentions:
ELVN
HCTI
SNES
NCNA
...
12 Health Care Stocks Moving In Friday's Intraday Session
3 months ago - By: Tiziana Life Sciences Ltd.
Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center
3 months ago - By: Tiziana Life Sciences Ltd.
Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center
3 months ago - By: Tiziana Life Sciences Ltd.
Tiziana Life Sciences to Present at the Bio International Convention
3 months ago - By: Tiziana Life Sciences Ltd.
Tiziana Life Sciences to Present at the Bio International Convention
4 months ago - By: Tiziana Life Sciences Ltd.
Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease
4 months ago - By: Tiziana Life Sciences Ltd.
Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease
4 months ago - By: Tiziana Life Sciences Ltd.
Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease
5 months ago - By: Tiziana Life Sciences Ltd.
Tiziana Life Sciences Announces Purchase of Shares by Chairman
5 months ago - By: Tiziana Life Sciences Ltd.
Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab
5 months ago - By: Tiziana Life Sciences Ltd.
Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab
5 months ago - By: Tiziana Life Sciences Ltd.
Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis
5 months ago - By: Yahoo Finance
- Mentions:
PHH
ATPC
MNPR
AGL
...
Why Tiziana Life Sciences Ltd (TLSA) is Surging in 2025
5 months ago - By: Tiziana Life Sciences Ltd.
Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
5 months ago - By: Tiziana Life Sciences Ltd.
Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
6 months ago - By: Tiziana Life Sciences Ltd.
Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial
6 months ago - By: Tiziana Life Sciences Ltd.
Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial
6 months ago - By: Tiziana Life Sciences Ltd.
Tiziana Life Sciences to Present at the 37th Annual Roth Conference
6 months ago - By: Tiziana Life Sciences Ltd.
Tiziana Life Sciences to Present at the 37th Annual Roth Conference
6 months ago - By: Tiziana Life Sciences Ltd.
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
6 months ago - By: Tiziana Life Sciences Ltd.
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
7 months ago - By: Tiziana Life Sciences Ltd.
Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
Please enable JavaScript to continue using this application.